A three-year retrospective study evaluating the efficacy of the Kerecis Omega3 rich fish skin used as grafts in the treatment of full-thickness diabetic foot ulcers was published recently in the journal Wounds.
The study was co-authored by Shannon Michael, DPM (St. Vincent Hospital, Indianapolis, and Food & Ankle Clinics of Arizona, Chandler, Ariz); Christopher Winters, DPM (American Health Network, St Vincent Hospital); and Maliha Khan, DPM (St Vincent Hospital).
In the trial, the fish skin was used to treat 51 patients with a total of 58 wounds. Investigators then compared the initial wound surface area with the final wound surface area to get the percentage of the total wounds healed over a 16-week treatment period.
The trial found that there was “a mean reduction of wound surface area by 87.57% and 35 wounds (more than 60%) were fully healed,” according to a media release from Kerecis.
In addition to the treatment, the authors reviewed 10 articles about fish skin grafts, three of which specifically evaluated lower-extremity ulcers.
Overall, the authors conclude that the study supports increased wound healing rates with the use of fish skin grafts for the treatment of diabetic wounds. Furthermore, rapid wound-surface-area reduction during the initial 4 weeks following graft application validates previous research that fish skin grafts enable diabetic wounds to transition from a chronic inflammatory stage to an acute wound environment for healing.
“This study is part of the growing body of evidence affirming the efficacy of the Kerecis fish-skin wound treatment,” G. Fertram Sigurjonsson, founder and CEO of Kerecis says in the release.
[Source(s): Kerecis, Business Wire]